Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306

被引：0

作者：

Pietrantonio, F. ^{[1
]}

Garassino, M. C. ^{[1
]}

Torri, V. ^{[2
]}

de Braud, F. ^{[1
]}

机构：

[1] Fdn IRCCS Ist Nazl Tumori, Med Oncol Unit 1, Milan, Italy

[2] Ist Ric Farmacol Mario Negri, Milan, Italy

来源：

ANNALS OF ONCOLOGY | 2012年 / 23卷 / 10期

关键词：

FLUOROURACIL; LEUCOVORIN; SURVIVAL;

D O I：

10.1093/annonc/mds332

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：2771 / 2772

页数：2

共 6 条

[1] Association of Computed Tomography Morphologic Criteria With Pathologic Response and Survival in Patients Treated With Bevacizumab for Colorectal Liver Metastases [J].

Chun, Yun Shin ;

Vauthey, Jean-Nicolas ;

Boonsirikamchai, Piyaporn ;

Maru, Dipen M. ;

Kopetz, Scott ;

Palavecino, Martin ;

Curley, Steven A. ;

Abdalla, Eddie K. ;

Kaur, Harmeet ;

Charnsangavej, Chusilp ;

Loyer, Evelyne M. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 302 (21) :2338-2344

[2] Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200 [J].

Giantonio, Bruce J. ;

Catalano, Paul J. ;

Meropol, Neal J. ;

O'Dwyer, Peter J. ;

Mitchell, Edith P. ;

Alberts, Steven R. ;

Schwartz, Michael A. ;

Benson, Al B., III .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (12) :1539-1544

[3] The Clinical Benefit of Bevacizumab in Metastatic Colorectal Cancer Is Independent of K-ras Mutation Status: Analysis of a Phase III Study of Bevacizumab with Chemotherapy in Previously Untreated Metastatic Colorectal Cancer [J].

Hurwitz, Herbert I. ;

Yi, Jing ;

Ince, Bwilliam ;

Novotny, William F. ;

Rosen, Oliver .

ONCOLOGIST, 2009, 14 (01) :22-28

[4] FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306 [J].

Stintzing, S. ;

von Weikersthal, L. Fischer ;

Decker, T. ;

Vehling-Kaiser, U. ;

Jaeger, E. ;

Heintges, T. ;

Stoll, C. ;

Giessen, C. ;

Modest, D. P. ;

Neumann, J. ;

Jung, A. ;

Kirchner, T. ;

Scheithauer, W. ;

Heinemann, V. .

ANNALS OF ONCOLOGY, 2012, 23 (07) :1693-1699

[5]

Tejpar S, 2012, J CLIN ONCOL

[6] Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status [J].

Van Cutsem, Eric ;

Kohne, Claus-Henning ;

Lang, Istvan ;

Folprecht, Gunnar ;

Nowacki, Marek P. ;

Cascinu, Stefano ;

Shchepotin, Igor ;

Maurel, Joan ;

Cunningham, David ;

Tejpar, Sabine ;

Schlichting, Michael ;

Zubel, Angela ;

Celik, Ilhan ;

Rougier, Philippe ;

Ciardiello, Fortunato .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15) :2011-2019

← 1 →